Biographical summary
Hancheng Cai, PhD, is a radiochemist and molecular imaging scientist. My clinical work focus on FDA cGMP PET drug production facility implementation and operation. Briefly, Dr. Cai oversees all the clinical production of PET tracers at Mayo Clinic Florida, leads a team to produce FDA-approved PET drugs for daily clinical use, and investigational tracers (F-18/C-11 labeled compounds as INDs) for PET imaging of cancer
cardiovascular disease, and neurological disorders in human.
Dr. Cai's research aims to developing novel radiopharmaceuticals for the imaging and therapy of cancer, neurological disorders, and cardiovascular diseases from preclinical discovery to clinical investigation. Specifically, his research work focus on development novel radiopharmaceuticals for PET imaging of cancer biology/metabolism, immunotherapy, inflammation, and neurological disorders.
Mayo Clinic locations
Education
- 2010
Postdoctoral Research Associate - Department of RadiologyUniversity of Southern California
- 2007
PhD - Radiopharmaceuticals ScienceGraduate School of Chinese Academy of Sciences
Activities and honors
Awards and honors
- 2015
New Investigator Award in Cancer ResearchUniversity of Texas Southwestern Medical Center
- 2010
Radiopharmaceutical Sciences Council Young Investigator AwardSociety of Nuclear Medicine
- 2010
57th SNM Travel AwardSociety of Nuclear Medicine
- 2009
Travel Award18th International Symposium on Radiopharmaceutical Sciences
- 2007
USC Biomedical Imaging Science Initiative Post doctorate FellowshipUniversity of Southern California
Professional memberships
- 2022 - present
American Chemical Society
- 2022 - present
Society of Nuclear Medicine and Molecular Imaging
- 2022 - present
Radioactive Drug Research Committee, Mayo Clinic Rochester Committees
- 2021 - present
World Molecular Imaging Society
- 2021 - present
Society of Nuclear Medicine and Molecular Imaging Committee on Radiopharmaceuticals (COR)
- 2020 - present
World Molecular Imaging Society (merger of AMI and SMI)
- 2020 - 2021
NIH Imaging Probes and Contrast Agents [IPCA] study section
- 2020 - present
Society of Nuclear Medicine and Molecular Imaging
- 2020 - present
World Molecular Imaging Society
- 2018 - present
Mayo Clinic Florida PET Radiochemistry Facility Steering Committee
- 2017 - present
Radiology Research Committee
- 2017 - present
Mayo Enterprise Radiology Nuclear Medicine Subspecialty Team and Operations Group
- 2017 - present
Mayo Pharmaceutical Formulary Committee Radiopharmaceutical task force
- 2014 - 2017
Member, Radioactive Drug Research Committee of UTSW
- 2014 - present
American Chemical Society
- 2014 - present
American Chemical Society
- 2011 - present
NSF Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Program
- 2009 - present
Society of Radiopharmaceutical Sciences
- 2009 - present
Society of Radiopharmaceutical Sciences
- 2008 - present
Society of Nuclear Medicine and Molecular Imaging
- 2008 - present
Society of Nuclear Medicine and Molecular Imaging
Publications